Cargando…

The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure

AIMS: Measurement of B‐type natriuretic peptide (BNP) or N‐terminal pro‐BNP is recommended as part of the diagnostic workup of patients with suspected heart failure (HF). We evaluated the diagnostic and prognostic utility of the novel urinary proteomic classifier HF1, compared with BNP, in HF. HF1 c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Campbell, Ross T., Jasilek, Adam, Mischak, Harald, Nkuipou‐Kenfack, Esther, Latosinska, Agnieszka, Welsh, Paul I., Jackson, Colette E., Cannon, Jane, McConnachie, Alex, Delles, Christian, McMurray, John J.V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373887/ https://www.ncbi.nlm.nih.gov/pubmed/32383555 http://dx.doi.org/10.1002/ehf2.12708

Ejemplares similares

Novel Urinary Peptidomic Classifier Predicts Incident Heart Failure
por: Zhang, Zhen‐Yu, et al.
Publicado: (2017)

Urinary peptides in heart failure: a link to molecular pathophysiology
por: He, Tianlin, et al.
Publicado: (2021)

Adverse Outcomes Associated With Interleukin-6 in Patients Recently Hospitalized for Heart Failure With Preserved Ejection Fraction
por: Mooney, Leanne, et al.
Publicado: (2023)

Relationship between CCR and NT-proBNP in Chinese HF Patients, and Their Correlations with Severity of HF
por: Lu, Zhigang, et al.
Publicado: (2014)

A novel urinary biomarker predicts 1-year mortality after discharge from intensive care
por: Nkuipou-Kenfack, Esther, et al.
Publicado: (2020)

Assessment of Metabolomic and Proteomic Biomarkers in Detection and Prognosis of Progression of Renal Function in Chronic Kidney Disease
por: Nkuipou-Kenfack, Esther, et al.
Publicado: (2014)

Comparison of different statistical approaches for urinary peptide biomarker detection in the context of coronary artery disease
por: Stanley, Eleanor, et al.
Publicado: (2016)

Reference Ranges for NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) and Risk Factors for Higher NT-proBNP Concentrations in a Large General Population Cohort
por: Welsh, Paul, et al.
Publicado: (2022)

STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure
por: Cannone, Valentina, et al.
Publicado: (2021)

Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial
por: Butt, Jawad H., et al.
Publicado: (2023)

Serum potassium in the PARADIGM‐HF trial
por: Ferreira, João Pedro, et al.
Publicado: (2020)

CKD273, a New Proteomics Classifier Assessing CKD and Its Prognosis
por: Argilés, Àngel, et al.
Publicado: (2013)

Plasma proteomic analysis reveals altered protein abundances in cardiovascular disease
por: Lygirou, Vasiliki, et al.
Publicado: (2018)

Promise and Implementation of Proteomic Prostate Cancer Biomarkers
por: Latosinska, Agnieszka, et al.
Publicado: (2018)

Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling
por: Docherty, Kieran F., et al.
Publicado: (2020)

Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)
por: Lee, Matthew M.Y., et al.
Publicado: (2020)

Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease
por: Pontillo, Claudia, et al.
Publicado: (2017)

Total Reactive Isocyanate Group (TRIG) Measurement: A Commentary
por: McConnachie, Glen, et al.
Publicado: (2023)

Urinary Proteomics Pilot Study for Biomarker Discovery and Diagnosis in Heart Failure with Reduced Ejection Fraction
por: Rossing, Kasper, et al.
Publicado: (2016)

Dementia‐related adverse events in PARADIGM‐HF and other trials in heart failure with reduced ejection fraction
por: Cannon, Jane A., et al.
Publicado: (2016)

Proteomic characterization of obesity-related nephropathy
por: Wendt, Ralph, et al.
Publicado: (2020)

Reproducibility Evaluation of Urinary Peptide Detection Using CE-MS
por: Mavrogeorgis, Emmanouil, et al.
Publicado: (2021)

‘Hearts and minds’: association, causation and implication of cognitive impairment in heart failure
por: Cannon, Jane A, et al.
Publicado: (2015)

Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial
por: Chatur, Safia, et al.
Publicado: (2022)

Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF
por: McEwan, Phil, et al.
Publicado: (2020)

Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF
por: McDowell, Kirsty, et al.
Publicado: (2022)

Urinary Proteomics to Support Diagnosis of Stroke
por: Dawson, Jesse, et al.
Publicado: (2012)

Which patients with heart failure should receive specialist palliative care?
por: Campbell, Ross T., et al.
Publicado: (2018)

Urinary Peptidomic Biomarker for Personalized Prevention and Treatment of Diastolic Left Ventricular Dysfunction
por: Zhang, Zhen‐Yu, et al.
Publicado: (2019)

Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM‐HF trial
por: Vardeny, Orly, et al.
Publicado: (2019)

Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM‐HF
por: Yeoh, Su E., et al.
Publicado: (2020)

Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo‐controlled multicentre trial
por: Cooper, Trond J., et al.
Publicado: (2022)

Identification of ageing-associated naturally occurring peptides in human urine
por: Nkuipou-Kenfack, Esther, et al.
Publicado: (2015)

Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer
por: Frantzi, Maria, et al.
Publicado: (2020)

Urine peptidome analysis in cardiorenal syndrome reflects molecular processes
por: Petra, Eleni, et al.
Publicado: (2021)

The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context
por: McMurray, John J V, et al.
Publicado: (2020)

Effect of sacubitril/valsartan on investigator‐reported ventricular arrhythmias in PARADIGM‐HF
por: Curtain, James P., et al.
Publicado: (2022)

Language Delay Is Not Predictable from Available Risk Factors
por: Wilson, Philip, et al.
Publicado: (2013)

Effect of IL-6 receptor blockade on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis
por: Welsh, Paul, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_g9is4hk9j7tl84g5brkg9fdak7